Evolution of the Average Target: Johnson & Johnson

Evolution of the Target Price: Johnson & Johnson

Changes in Analyst Recommendations: Johnson & Johnson

12166896c0527738.z2pKIA4UW0DRV7-Xtp2atDISk_UAUMti2ID83qRCx-o.nV0DcEQhPXKDDffVhK7O00J2p6xVE_847vOQvZMtrr-YOzx0dGYMLZIe7g~090a4526f70aa8871af053e056833d4a
04-09 Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says MT
04-07 Citigroup Adjusts Price Target on Johnson & Johnson to $285 From $274, Maintains Buy Rating MT
04-07 Guggenheim Adjusts Price Target on Johnson & Johnson to $244 From $240, Maintains Buy Rating MT
03-30 Johnson & Johnson's Vision Segment Targets Up to High-Single Digit Long-Term Growth, RBC Says MT
03-30 Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says MT
03-30 Nanobiotix in the red despite positive Phase 2 trial data Zonebourse
03-19 Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says MT
03-19 Barclays Adjusts Price Target on Johnson & Johnson to $234 From $217, Maintains Equalweight Rating MT
03-18 Global markets live: Nvidia, Amazon, Oracle, Lululemon, Airbus… Zonebourse
03-17 HSBC Adjusts Price Target on Johnson & Johnson to $280 From $265, Maintains Buy Rating MT
03-16 Bernstein: Risk in Alcon's Implantables Business 'Manageable,' Already Priced In MT
03-11 Citigroup Adjusts Price Target on Johnson & Johnson to $274 From $250, Maintains Buy Rating MT
03-05 United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says MT
03-05 JPMorgan Adjusts Price Target on Johnson & Johnson to $250 From $225, Maintains Neutral Rating MT
02-19 Rothschild & Co Redburn Adjusts PT on Johnson & Johnson to $210 From $180, Maintains Neutral Rating MT
02-03 Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says MT
02-03 RBC Raises Price Target on Johnson & Johnson to $255 From $240, Keeps Outperform Rating MT
01-30 HSBC Adjusts Johnson & Johnson PT to $265 From $240, Maintains Buy Rating MT
01-29 Daiwa Securities Adjusts Price Target on Johnson & Johnson to $237 From $203, Maintains Outperform Rating MT
01-28 Morgan Stanley Upgrades Johnson & Johnson to Overweight From Equalweight, Adjusts PT to $262 From $200 MT
01-23 Argus Raises Price Target on Johnson & Johnson to $240 From $210 MT
01-23 Bernstein Adjusts Price Target on Johnson & Johnson to $225 From $208, Maintains Market Perform Rating MT
01-23 Guggenheim Adjusts Price Target on Johnson & Johnson to $240 From $227, Maintains Buy Rating MT
01-22 Johnson & Johnson Reports Modest Q4 Beat but Stock Seems Fairly Valued, Morgan Stanley Says MT
01-22 Goldman Sachs Adjusts Price Target on Johnson & Johnson to $250 From $240, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+1.45%
+28.76%
+19.76%
+7.36%
+6.46%
-0.37%
+0.19%
+13.57%
+28.72%
Average +11.77%
Weighted average by Cap. +13.53%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
238.46USD
Average target price
241.92USD
Spread / Average Target
+1.45%
High Price Target
285.00USD
Spread / Highest target
+19.52%
Low Price Target
155.00USD
Spread / Lowest Target
-35.00%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Citigroup
Guggenheim
Barclays
HSBC
JPMorgan Chase
Rothschild & Co Redburn
RBC Capital Markets
Daiwa Securities
Morgan Stanley
Argus
Bernstein
TD Cowen
Goldman Sachs
Leerink Partners
Raymond James
Wolfe Research
Scotiabank
Stifel Nicolaus
Wells Fargo Securities
BofA Securities
UBS
DBS Bank
Redburn Atlantic
DZ Bank
Atlantic Equities
Credit Suisse
SVB Securities LLC
DA Davidson
SVB Financial
Sanford Bernstein
Cantor Fitzgerald
J.P. Morgan Chase
Cowen
SVB Leerink
RBC Brandon Henry
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
238.46USD
Average target price
241.92USD
Spread / Average Target
+1.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. Consensus Johnson & Johnson